Abstract
A variety of neurologic conditions may influence the selection and conduction of anesthesia. The pharmacodynamics of many anesthetics are often directly altered by neurologic disorders. Most anesthetic agents are reversibly neurotoxic, and thus monitoring the recovery of neurologic function after anesthesia becomes complicated. In addition, many neurologic disorders are rare resulting in limited anesthetic reports in the literature. The combination of these factors requires maximum caution in planning the administration of anesthesia.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dierdorf SF, Walton JS. Rare and coexisting diseases. In: Barash PG, Cullen BF, Stoelting RK, Cahalan MK, Stock MC, editors. Clinical anesthesia. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 622–43.
Kivela JE, Sprung J, Southorn PA, Watson JC, Weingarten TN. Anesthetic management of patients with Huntington disease. Anesth Analg. 2010;110(2):515.
Pasternak JJ, Lanier WL. Diseases affecting the brain. In: Hines RL, Marschall KE, editors. Stoelting’s anesthesia and co-existing disease. 5th ed. Philadelphia: Churchill Livingstone; 2008. p. 199–237.
Pasternak JJ, Lanier WL. Spinal cord disorders. In: Hines RL, Marschall KE, editors. Stoelting’s anesthesia and co-existing disease. 5th ed. Philadelphia: Churchill Livingstone; 2008. p. 239–47.
Roizen MF, Fleisher LA. Anesthetic implications of concurrent disease. In: Miller RD, editor. Miller’s anesthesia. 7th ed. Philadelphia: Churchill Livingstone; 2010. p. 1067–149.
Shaikh S, Verma H. Parkinson’s disease and anesthesia. Indian J Anaesth. 2011;55(3):228–34.
Scott BK, Baranov D. Neurologic diseases. In: Fleisher LA, editor. Anesthesia and uncommon diseases. 6th ed. Philadelphia: Elsevier Saunders; 2012. p. 251–94.
Stoelting RK, Hillier SC. Pharmacology and physiology in anesthetic practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
Ruottinen HM, Rinne UK. COMT inhibition in the treatment of Parkinson’s disease. J Neurol. 1998;245(11 Suppl 3):25–34.
Thrower BW. Relapse management in multiple sclerosis. Neurologist. 2009;15(1):1–5.
Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporine. Clin Pharmacokinet. 1996;30(2):141–79.
Fonseca V, Harvard CW. Long term treatment of myasthenia gravis with azathioprine. Postgrad Med J. 1990;66(772):102–5.
Kaye AD, Lasala MF, Baluch A. Preanesthetic assessment of the patient with a Stroke. Anesthesia News. 2012;39(2):19–23.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Chemical Structures
Chemical Structure 30.1
Levodopa
Chemical Structure 30.2
Benzatropine
Chemical Structure 30.3
Cyclophosphamide
Chemical Structure 30.4
Riluzole
Chemical Structure 30.5
Azathioprine
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bustillo, M., Vecchione, T. (2015). Neuropharmacologic Agents for Neurologic Conditions. In: Kaye, A., Kaye, A., Urman, R. (eds) Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8948-1_30
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8948-1_30
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-8947-4
Online ISBN: 978-1-4614-8948-1
eBook Packages: MedicineMedicine (R0)